Pangenomic Health Inc. NARA
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -70.23% | -68.45% | -88.86% | -24.48% | 134.07% |
| Gross Profit | 70.23% | 68.45% | 88.86% | 24.48% | -134.07% |
| SG&A Expenses | 87.95% | 256.87% | 532.04% | 1,245.75% | 70.86% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | -93.33% | -95.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.12% | 134.79% | 49.19% | 803.52% | 78.78% |
| Operating Income | -31.12% | -134.79% | -49.19% | -803.52% | -78.78% |
| Income Before Tax | -68.21% | -138.52% | -3.48% | -783.23% | 84.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.21% | -138.52% | -3.48% | -783.23% | 84.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.21% | -138.52% | -3.48% | -783.23% | 84.56% |
| EBIT | -31.12% | -134.79% | -49.19% | -803.52% | -78.78% |
| EBITDA | -31.13% | -134.84% | -49.20% | -814.87% | -81.23% |
| EPS Basic | 8.74% | 32.64% | 78.45% | -263.72% | 93.80% |
| Normalized Basic EPS | 8.53% | 32.37% | 68.28% | -261.27% | 39.72% |
| EPS Diluted | 8.74% | 32.64% | 78.45% | -263.72% | 93.80% |
| Normalized Diluted EPS | 8.53% | 32.37% | 68.28% | -261.27% | 39.72% |
| Average Basic Shares Outstanding | 83.71% | 253.93% | 380.22% | 143.42% | 149.00% |
| Average Diluted Shares Outstanding | 83.71% | 253.93% | 380.22% | 143.42% | 149.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |